Science Allocation and Research Acceleration Act

Generated by Optimitron OBG + Gemini (search-grounded structured research packet) Based on OECD efficient frontier (28 countries, rank 25/28) Category: Science / NASA | Overspend: 1.9x | US Rank: 25/28

Proposed bill title: Science Allocation and Research Acceleration Act

Summary

Keeps science bills focused on research allocation, validation throughput, and translational results instead of generic spending manifestos, returning verified net savings to citizens.

Findings

• The NIH Allocation Bottleneck: The NIH allocates only 3.3% of its budget to clinical trials, stranding promising discoveries in a 40% 'Valley of Death' attrition rate. 1 2
• Pragmatic Trial Arbitrage: Pragmatic clinical trials cost 97.7% less than traditional Phase 3 trials ($929 vs $41,000 per patient), offering a 44x cost reduction arbitrage that can dramatically scale research throughput. 3 4
• The 8.2-Year Efficacy Lag: Post-safety regulatory delays for efficacy testing cost 8.2 years per drug, resulting in millions of preventable deaths as patients wait years for access to safe treatments. 5 6
• The Patient Participation Ceiling: Current trial participation is artificially capped at 0.08%, despite 44.8% of patients being willing to participate, leaving a theoretical 560x expansion in trial capacity untapped. 7 8

Purpose

To move the United States from rank 25/28 toward the Netherlands's top-tier science spending efficiency by replacing the NIH and FDA with high-throughput, validation-first institutions, eliminating the 8.2-year efficacy lag, and returning structural savings to citizens.

Public-Goods and Market Framework

• Non-Rivalrous Medical Knowledge and Open Data Commons: The primary market failure in medical research is that knowledge is a non-rivalrous public good. The current system attempts to solve this via patents, which create temporary monopolies and restrict access. By subsidizing pragmatic trials directly and mandating that all results (positive and negative) be published in an open data commons, the dIH treats clinical data as a true public good. This maximizes the 2x R&D spillover multiplier and accelerates the discovery process for all researchers globally. 9

Public Choice / Capture Analysis

• Dismantling the Academic-Grant Industrial Complex: The legacy NIH system is captured by an academic-grant industrial complex where researchers spend up to half their time writing grants, and institutions extract massive overhead rates. This is a classic public choice failure where concentrated interests (universities) capture the budget process at the expense of the diffuse public (patients waiting for cures). The dIH bypasses this by capping overhead at 3% and directing 97% of funds to patient subsidies, aligning incentives directly with translational throughput. 10

Pareto / Compensation Analysis

• Compensated Pareto: The transition from the NIH/FDA to the dIH/dFDA creates massive societal surplus by accelerating cures and reducing costs. However, legacy grant administrators, basic researchers reliant on NIH grants, and regulatory compliance consultants will lose their current income streams. Likely losers: NIH grant administrators, University overhead departments, FDA compliance consultants. 11 Compensation mechanism: A portion of the initial year's savings will be allocated to a transition fund providing severance, retraining, and early retirement packages for displaced federal workers and affected academic staff.

Key Provisions

Establishment of the Optimal Institutes of Health (dIH)

Summary: Replaces the NIH with the dIH, mandating a shift to validation-first research allocation where 97% of the budget funds pragmatic clinical trials and 3% funds overhead. 1 11 Modeled on: Netherlands NWO/ZonMw efficiency targets, Wishonia dIH

Market mechanism: Direct patient subsidies for trial participation proportional to disease burden (DALYs). Public-goods justification: Medical knowledge and clinical trial data are non-rivalrous public goods with a 2x R&D spillover multiplier. Public-choice rationale: Legacy grant systems incentivize scientists to spend time writing proposals for peer review rather than conducting trials; direct patient subsidies bypass academic rent-seeking. Pareto status: Compensated Pareto Pareto rationale: Citizens gain faster cures and lower taxes; displaced academic researchers and grant administrators receive transition assistance. Compensation mechanism: Transition funding and severance packages for legacy NIH grant administrators and basic researchers. Residual rent handling: Open data commons for all trial results (positive and negative) prevents data hoarding and publication bias.

Capture risks:

• Academic institutions lobbying to retain basic research carve-outs.
• Incumbent research hospitals attempting to monopolize pragmatic trial networks.

Anti-capture safeguards:

• Statutory cap of 3% on administrative overhead.
• Algorithmic funding allocation based on DALYs rather than peer-review committees.

Corruption risks:

• Fraudulent patient enrollment in pragmatic trials to capture subsidies.
• Falsification of trial data to secure milestone payments.

Anti-corruption safeguards:

• Cryptographic identity verification for patients.
• Open-ledger tracking of all trial fund flows via IPFS.

Operative clauses:

• The National Institutes of Health is hereby abolished and replaced by the Optimal Institutes of Health.
• The dIH shall allocate no less than 97% of its annual budget directly to pragmatic clinical trial subsidies.

Expected impacts:

• Clinical Trial Funding Ratio: 97% of budget. Inverts the current 3.3% allocation to maximize translational throughput. 1

Implementation timeline: 24 months to spin down NIH grant programs and launch dIH patient subsidy portals.

Objections and responses:

• Objection: Basic research is the foundation of all future discoveries. Response: The current bottleneck is not basic discovery but translational validation; the 40% Valley of Death must be cleared first. 2

Establishment of the Decentralized FDA (dFDA)

Summary: Replaces the FDA with the dFDA, decoupling safety testing from efficacy testing to eliminate the 8.2-year regulatory lag and replacing binary approvals with real-time Outcome Labels. 5 Modeled on: Wishonia dFDA

Market mechanism: Real-time Outcome Labels allow doctors and patients to make informed choices based on continuously updated real-world data rather than waiting for centralized efficacy approval. 5 Public-goods justification: Accurate, real-time efficacy and side-effect data is a public good that corrects information asymmetry in the medical market. 5 Public-choice rationale: Centralized regulators are incentivized to delay approvals to avoid visible Type I errors (approving a bad drug), ignoring the invisible Type II errors (patients dying while waiting). 5 Pareto status: Strict Pareto Pareto rationale: Patients get access to safe drugs 8.2 years faster, and pharmaceutical companies save $1.56B per drug in Phase 2/3 costs. 5 Compensation mechanism: None required as the mechanism strictly expands patient choice and reduces industry costs. 5 Residual rent handling: User fees for safety testing are transparently priced and openly competed among certified independent testing labs. 5

Capture risks:

• Incumbent pharmaceutical companies lobbying to maintain high regulatory barriers to protect their monopolies from generic or novel competition. 5
• Regulatory capture by large hospital networks controlling the Outcome Label data feeds. 5

Anti-capture safeguards:

• Statutory mandate that any drug passing Phase 1 safety testing must be immediately available for prescription with a provisional Outcome Label. 5
• Open API requirements for all EHR systems feeding the Outcome Label database. 5

Corruption risks:

• Manipulation of real-world data streams to artificially inflate a drug's Outcome Label. 5
• Bribing independent safety testing labs to pass toxic compounds. 5

Anti-corruption safeguards:

• Decentralized, cryptographically signed data capture directly from electronic health records (EHRs) to the dFDA ledger. 5
• Randomized, double-blind auditing of safety testing labs by the dGAO. 5

Operative clauses:

• The Food and Drug Administration is hereby abolished and replaced by the Decentralized FDA.
• Upon successful completion of Phase 1 safety testing, treatments shall be immediately accessible to patients.

Expected impacts:

• Time from Safety Proof to Patient Access: 0 years. Eliminates the 8.2-year efficacy lag. 5

Implementation timeline: 18 months to transition from binary approvals to the Outcome Label system.

Objections and responses:

• Objection: Efficacy testing before market release prevents consumers from spending money on useless drugs. Response: Real-time Outcome Labels provide better, continuous efficacy data than static trials, and patients with terminal illnesses cannot afford to wait 8 years. 6

Optimization Dividend and Savings Disposition

Summary: Mandates that all structural savings generated by the transition to the dIH and dFDA, estimated at up to $314B annually, be returned directly to citizens as a cash dividend. 12 Modeled on: Wishonia Optimization Dividend, implementation_then_dividend rule

Market mechanism: Direct cash transfers to citizens. 12 Public-goods justification: Returning surplus tax revenue directly to citizens maximizes individual utility and prevents bureaucratic budget maximization. 12 Public-choice rationale: Agencies naturally seek to absorb any efficiency savings into new programs; a statutory dividend forces the return of surplus funds to the taxpayers. 12 Pareto status: Compensated Pareto Pareto rationale: Citizens receive a direct cash benefit, offsetting any perceived loss of legacy government programs. 12 Compensation mechanism: The dividend itself compensates taxpayers for past inefficiencies. 12 Residual rent handling: Dividend distribution is automated and formulaic, preventing political targeting of funds. 12

Capture risks:

• Congress attempting to divert the savings into other spending categories before the dividend is paid. 12
• Special interest groups lobbying for carve-outs from the savings pool. 12

Anti-capture safeguards:

• Automatic, algorithmic distribution of the dividend triggered by dCBO and dGAO verified savings reports. 12
• Statutory prohibition on redirecting dIH/dFDA savings to other federal agencies. 12

Corruption risks:

• Embezzlement during the dividend distribution process. 12
• Identity fraud to claim multiple dividends. 12

Anti-corruption safeguards:

• Public ledger tracking of aggregate dividend disbursements. 12
• Cryptographic identity verification for dividend recipients. 12

Operative clauses:

• All verified net savings from the abolition of the NIH and FDA shall be deposited into the Optimization Dividend Fund.
• The Fund shall distribute its balance annually to all eligible citizens.

Expected impacts:

• Annual Savings Returned to Citizens: Up to $314B/yr. Represents the elimination of the 1.9x science/health overspend compared to the Netherlands baseline. 12

Implementation timeline: First dividend paid 12 months after the full operational launch of the dIH and dFDA.

Objections and responses:

• Objection: Savings should be reinvested into more research. Response: The dIH's 44x cost efficiency means we can fund vastly more research while still returning massive savings to citizens. 3

Reallocation Plan

• Shift from Basic Research to Pragmatic Validation: The bill reallocates the current $47B NIH budget. Currently, only 3.3% goes to clinical trials. The new dIH will allocate 97% to pragmatic trials. The $1.56B per-drug cost burden on the private sector will be drastically reduced by the dFDA's real-world evidence model. The resulting structural savings across the federal health and science portfolio, targeting the 1.9x overspend relative to the Netherlands, will be routed to the Optimization Dividend. 1 11

Fiscal Impact

• Elimination of the 1.9x Overspend and $314B Dividend: By adopting the efficiency models of the Netherlands and leveraging the 44x cost reduction of pragmatic trials, the US can eliminate its 1.9x overspend in science and health research. This generates an estimated $314B in annual structural savings across the broader health and science budget, which will be distributed as an Optimization Dividend after accounting for transition costs. 12

Implementation Timeline

• Phased Transition to High-Throughput Science: Months 1-12: Establish the dIH and dFDA statutory frameworks; begin spinning down NIH grant programs. Months 13-24: Launch the dIH patient subsidy portal and the dFDA Outcome Label database; transition all Phase 1-cleared drugs to provisional access. Month 25+: First distribution of the Optimization Dividend from realized savings. 5

Evaluation & Sunset Provisions

• Clinical Trial Patient Participation Rate: Increase from 0.08% to 10% within 5 years.. Unlocking the physical scaling limit of trial participation is essential for clearing the therapeutic queue. 7
• Time from Safety Proof to Patient Access: 0 years (immediate provisional access).. Eliminating the 8.2-year efficacy lag saves lives immediately and reduces the cost of drug development. 5
• Cost per Pragmatic Trial Patient: Under $1,000 per patient.. Maintaining the 44x cost arbitrage is necessary to fund the expanded trial volume without increasing the budget. 3

Evidence Appendix

• NIH Clinical Trials Spending Percentage: The NIH allocates approximately 3.3% of its budget to clinical trials, highlighting a severe underfunding of translational validation. 1
• Pragmatic Trials Cost Advantage: Pragmatic trials cost approximately $929 per patient, compared to $41,000 for traditional Phase 3 trials, offering a 97.7% cost reduction. 3 4
• Efficacy Lag and Preventable Deaths: The regulatory delay for efficacy testing post-safety verification averages 8.2 years, contributing to millions of preventable deaths historically. 5 6

Open Questions

• What is the optimal exact ratio of basic to translational research for maximum QALY generation?
• How quickly can legacy hospital IT systems integrate with a decentralized pragmatic trial data-capture framework?
• What is the optimal mechanism to price provisionally approved drugs before their efficacy is definitively proven?
• How can we ensure demographic and genetic diversity when scaling decentralized trial participation globally?
• Which disease categories should be prioritized in the first 5 years of the queue clearance mandate?
• What is the exact transition cost required to fully spin up the Decentralized FDA before the dividend can be paid?

---

Sources

1. pmc.ncbi.nlm.nih.gov
2. pmc.ncbi.nlm.nih.gov
3. commonfund.nih.gov
4. ncbi.nlm.nih.gov
5. go.bio.org
6. nber.org
7. fightcancer.org
8. trialsjournal.biomedcentral.com
9. rethinkingclinicaltrials.org
10. elifesciences.org
11. nih.gov
12. obg.warondisease.org

---

Metadata

• Search queries:
• Sources cited: 12
• Claims with citations: 25
• Rendered bill title: Science Allocation and Research Acceleration Act
• Structured research model: gemini-3.1-pro-preview
• Structured findings: 4
• Structured provisions: 3
• Structured evaluation metrics: 3
• Evidence bundle model: gemini-3.1-pro-preview
• Evidence bundle parameters: 22
• Evidence bundle insights: 6
• Evidence bundle summary: To move the US toward the Netherlands's after-tax median income performance, this legislation fundamentally reforms federal science and health research allocation. It targets the 1.9x overspend by dismantling the inefficient legacy models of the NIH and FDA. The bill establishes the Optimal Institutes of Health to mandate a shift from basic research to translational validation, and a Decentralized FDA to replace $41,000-per-patient traditional trials with $929 pragmatic trials. By decoupling safety from efficacy testing, the bill eliminates the 8.2-year regulatory lag, unlocking a 500x physical scaling limit in patient participation. This high-throughput engineering approach compresses the 443-year queue for curing remaining diseases into just 36 years. Following the 'implementation_then_dividend' rule, the structural savings generated by these market mechanisms and anti-capture safeguards will fund the transition, with the remaining $314B/yr returned directly to citizens as an Optimization Dividend.
• Category: Science / NASA
• Model country: Netherlands
• Wishonia package: Science Allocation and Research Acceleration Act
• Wishonia agencies: Optimal Institutes of Health (primary); Decentralized FDA (supporting); Optimal Policy Generator (supporting); Decentralized Accountability Office (supporting); Optimal Budget Generator (supporting)
• Default savings disposition: implementation_then_dividend
• Overspend ratio: 1.9x
• Potential savings: $314B/yr
• Related OPG policy briefs: Science / NASA: Adopt Netherlands's Approach (reallocate, grade B)